These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36398467)

  • 21. Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa.
    Pitance V; Désage S; Lienhart A; Meunier S; Chamouard V
    Haemophilia; 2021 May; 27(3):e368-e375. PubMed ID: 33780111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
    Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
    Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
    Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
    Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.
    Polack B; Trossaërt M; Cousin M; Baffert S; Pruvot A; Godard C
    Haemophilia; 2021 Jan; 27(1):e1-e11. PubMed ID: 33210412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
    Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
    Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
    McMullen S; Buckley B; Hall E; Kendter J; Johnston K
    Value Health; 2017 Jan; 20(1):93-99. PubMed ID: 28212975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.
    Nolan B; Mahlangu J; Pabinger I; Young G; Konkle BA; Barnes C; Nogami K; Santagostino E; Pasi KJ; Khoo L; Winding B; Yuan H; Fruebis J; Rudin D; Oldenburg J
    Haemophilia; 2020 May; 26(3):494-502. PubMed ID: 32227570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.
    Meeks SL; Lacroix-Desmazes S
    Haemophilia; 2020 Nov; 26(6):958-965. PubMed ID: 32885562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein.
    Oldenburg J; Kulkarni R; Srivastava A; Mahlangu JN; Blanchette VS; Tsao E; Winding B; Dumont J; Jain N
    Haemophilia; 2018 Jan; 24(1):77-84. PubMed ID: 29082639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.
    Shapiro AD; Mahlangu JN; Perry D; Pasi J; Quon DV; Chowdary P; Tsao E; Li S; Innes A; Pierce GF; Allen GA
    Haemophilia; 2017 May; 23(3):392-399. PubMed ID: 28220631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors.
    Cortesi PA; Castaman G; Trifirò G; Creazzola SS; Improta G; Mazzaglia G; Molinari AC; Mantovani LG
    Thromb Haemost; 2020 Feb; 120(2):216-228. PubMed ID: 31887777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The societal burden of haemophilia A. III - The potential impact of emicizumab on costs of haemophilia A in Australia.
    Brown LJ; La HA; Li J; Brunner M; Snoke M; Kerr AM
    Haemophilia; 2020 Aug; 26 Suppl 5():21-29. PubMed ID: 32935399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab.
    Camelo RM; Barbosa MM; Araújo MS; Muniz RL; Guerra AA; Godman B; Rezende SM; Acurcio FA; Martin AP; Alvares-Teodoro J
    Value Health Reg Issues; 2023 Mar; 34():31-39. PubMed ID: 36463835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emicizumab: A Review in Haemophilia A.
    Blair HA
    Drugs; 2019 Oct; 79(15):1697-1707. PubMed ID: 31542880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
    Kempton C; Trask P; Parnes A; Niggli M; Campinha-Bacote A; U Callaghan M; O'Connell N; Paz-Priel I; Mahlangu JN
    Haemophilia; 2021 Mar; 27(2):221-228. PubMed ID: 33506955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
    Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
    Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.